Advertisement
U.S. markets closed

Calithera Biosciences, Inc. (CALA)

Other OTC - Other OTC Delayed Price. Currency in USD
0.02000.0000 (0.00%)
At close: 10:34AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0200
Open0.0200
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.0200 - 0.0200
52 Week Range0.0100 - 0.4999
Volume58
Avg. Volume10,460
Market Cap97,450
Beta (5Y Monthly)-0.22
PE Ratio (TTM)N/A
EPS (TTM)-7.9400
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CALA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CALITHERA BIOSCIENCES INC
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    15 hours agoArgus Research
View more
  • GlobeNewswire

    Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

    Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”). In January 2023, the Company announced its intention to com